These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1442 related articles for article (PubMed ID: 30846391)

  • 1. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.
    Kowalski PS; Rudra A; Miao L; Anderson DG
    Mol Ther; 2019 Apr; 27(4):710-728. PubMed ID: 30846391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
    Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
    Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
    Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
    ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-viral strategies for delivering genome editing enzymes.
    Li J; Røise JJ; He M; Das R; Murthy N
    Adv Drug Deliv Rev; 2021 Jan; 168():99-117. PubMed ID: 32931860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: Clinical applications.
    Masarwy R; Stotsky-Oterin L; Elisha A; Hazan-Halevy I; Peer D
    Adv Drug Deliv Rev; 2024 Aug; 211():115359. PubMed ID: 38857763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene editing therapeutics based on mRNA delivery.
    Popovitz J; Sharma R; Hoshyar R; Soo Kim B; Murthy N; Lee K
    Adv Drug Deliv Rev; 2023 Sep; 200():115026. PubMed ID: 37516409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Materials for non-viral intracellular delivery of messenger RNA therapeutics.
    Kauffman KJ; Webber MJ; Anderson DG
    J Control Release; 2016 Oct; 240():227-234. PubMed ID: 26718856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.
    Trepotec Z; Lichtenegger E; Plank C; Aneja MK; Rudolph C
    Mol Ther; 2019 Apr; 27(4):794-802. PubMed ID: 30655211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
    Tang H; Zhao X; Jiang X
    Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.
    Ma T; Chen X; Wang M
    Chembiochem; 2023 May; 24(9):e202200801. PubMed ID: 36780174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
    Wang C; Zhang Y; Dong Y
    Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA delivery technologies: Toward clinical translation.
    Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
    Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer-Based mRNA Delivery Strategies for Advanced Therapies.
    Yang W; Mixich L; Boonstra E; Cabral H
    Adv Healthc Mater; 2023 Jun; 12(15):e2202688. PubMed ID: 36785927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short cell-penetration peptide conjugated bioreducible polymer enhances gene editing of CRISPR system.
    Wang X; Cai C; Lv W; Chen K; Li J; Liao K; Zhang Y; Huang H; Lin Y; Rong Z; Duan X
    J Nanobiotechnology; 2024 May; 22(1):284. PubMed ID: 38790037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid Nanoparticle Systems for Enabling Gene Therapies.
    Cullis PR; Hope MJ
    Mol Ther; 2017 Jul; 25(7):1467-1475. PubMed ID: 28412170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing.
    Cheng Q; Wei T; Farbiak L; Johnson LT; Dilliard SA; Siegwart DJ
    Nat Nanotechnol; 2020 Apr; 15(4):313-320. PubMed ID: 32251383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Development of mRNA-Based Therapeutics.
    Huang L; Zhang L; Li W; Li S; Wen J; Li H; Liu Z
    Curr Top Microbiol Immunol; 2022; 440():147-166. PubMed ID: 32683507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
    Guo P; Yang J; Huang J; Auguste DT; Moses MA
    Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.